DNIB Unwind (NASDAQ: BIND) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare DNIB Unwind to similar businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Risk and Volatility

DNIB Unwind has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Comparatively, DNIB Unwind’s competitors have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares DNIB Unwind and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
DNIB Unwind N/A N/A -0.44
DNIB Unwind Competitors $224.58 million $58.11 million -0.98

DNIB Unwind’s competitors have higher revenue and earnings than DNIB Unwind. DNIB Unwind is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares DNIB Unwind and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DNIB Unwind -201.34% -3,980.56% -123.62%
DNIB Unwind Competitors -912.91% -186.15% -28.31%

Analyst Recommendations

This is a summary of current recommendations and price targets for DNIB Unwind and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DNIB Unwind 0 0 0 0 N/A
DNIB Unwind Competitors 166 554 1215 16 2.55

As a group, “Biotechnology” companies have a potential upside of 58.44%. Given DNIB Unwind’s competitors higher probable upside, analysts clearly believe DNIB Unwind has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 18.5% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

DNIB Unwind competitors beat DNIB Unwind on 6 of the 8 factors compared.

DNIB Unwind Company Profile

DNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company’s subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.

Receive News & Stock Ratings for DNIB Unwind Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DNIB Unwind Inc and related stocks with our FREE daily email newsletter.